Literature DB >> 26231341

Echocardiographic evaluation of pre-diagnostic development in young relatives genetically predisposed to hypertrophic cardiomyopathy.

Morten K Jensen1, Ole Havndrup2, Michael Christiansen3, Paal S Andersen3, Anna Axelsson4, Lars Køber4, Henning Bundgaard4.   

Abstract

Identification of the first echocardiographic manifestations of hypertrophic cardiomyopathy may be important for clinical management and our understanding of the pathogenesis. We studied the development of pre-diagnostic echocardiographic changes in young relatives to HCM patients during long-term years follow-up. HCM-relatives not fulfilling the diagnostic criteria for HCM and age of <18 years were included in this study. We performed echocardiographic evaluations at inclusion and after 12 ± 1 years follow-up. Based on family screening of 11 sarcomere genes, CRYAB, α-GAL, and titin, we evaluated: (1) non-carriers (known family mutation ruled out-controls), (2) carriers (phenotype negative gene mutation carriers) and (3) phenotype negative relatives with unknown genetic status (relatives from families without identified mutations). At inclusion (age 11 ± 5 years), there were no differences in echocardiographic chamber dimensions, systolic or diastolic function between the three groups. During follow-up (age 23 ± 5 years), carriers (n = 8) developed lower left ventricular end-diastolic dimension (LVEDd) compared to non-carriers (n = 23) (41 ± 4 vs. 46 ± 4 mm; p = 0.04) and a higher ratio of early left ventricular filling velocity and early diastolic velocity of lateral mitral annulus (E/e' 6 ± 1 vs. 5 ± 1; p = 0.003). No significant differences in LVEDd or E/e' were found between relatives with unknown genetic status (n = 24) and non-carriers though Z-scores for these parameters were >2 in a subset of relatives with unknown genetic status. Children carrying pathogenic sarcomere gene mutations develop reduced LVEDd and increased E/e' as first pre-diagnostic echocardiographic manifestations during follow-up into adulthood.

Entities:  

Keywords:  Cardiomyopathy; Carriers; Children; Diastolic function; Dimensions; Family screening; Hypertrophy; Inherited heart disease; Left ventricle; Sarcomere gene mutation

Mesh:

Substances:

Year:  2015        PMID: 26231341     DOI: 10.1007/s10554-015-0723-x

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  26 in total

1.  A formula to estimate the approximate surface area if height and weight be known. 1916.

Authors:  D Du Bois; E F Du Bois
Journal:  Nutrition       Date:  1989 Sep-Oct       Impact factor: 4.008

2.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology.

Authors:  Roberto M Lang; Michelle Bierig; Richard B Devereux; Frank A Flachskampf; Elyse Foster; Patricia A Pellikka; Michael H Picard; Mary J Roman; James Seward; Jack S Shanewise; Scott D Solomon; Kirk T Spencer; Martin St John Sutton; William J Stewart
Journal:  J Am Soc Echocardiogr       Date:  2005-12       Impact factor: 5.251

3.  T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy.

Authors:  Carolyn Y Ho; Siddique A Abbasi; Tomas G Neilan; Ravi V Shah; Yucheng Chen; Bobak Heydari; Allison L Cirino; Neal K Lakdawala; E John Orav; Arantxa González; Begoña López; Javier Díez; Michael Jerosch-Herold; Raymond Y Kwong
Journal:  Circ Cardiovasc Imaging       Date:  2013-04-02       Impact factor: 7.792

4.  Familial hypertrophic cardiomyopathy associated with a novel missense mutation affecting the ATP-binding region of the cardiac beta-myosin heavy chain.

Authors:  H Bundgaard; O Havndrup; P S Andersen; L A Larsen; N J Brandt; J Vuust; K Kjeldsen; M Christiansen
Journal:  J Mol Cell Cardiol       Date:  1999-04       Impact factor: 5.000

Review 5.  Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy.

Authors:  Barry J Maron; J G Seidman; Christine E Seidman
Journal:  J Am Coll Cardiol       Date:  2004-12-07       Impact factor: 24.094

6.  Early changes in apical rotation in genotype positive children with hypertrophic cardiomyopathy mutations without hypertrophic changes on two-dimensional imaging.

Authors:  Jonathan Forsey; Lee Benson; Evelyn Rozenblyum; Mark K Friedberg; Luc Mertens
Journal:  J Am Soc Echocardiogr       Date:  2013-12-08       Impact factor: 5.251

7.  How do hypertrophic cardiomyopathy mutations affect myocardial function in carriers with normal wall thickness? Assessment with cardiovascular magnetic resonance.

Authors:  Tjeerd Germans; Iris K Rüssel; Marco J W Götte; Marieke D Spreeuwenberg; Pieter A Doevendans; Yigal M Pinto; Rob J van der Geest; Jolanda van der Velden; Arthur A M Wilde; Albert C van Rossum
Journal:  J Cardiovasc Magn Reson       Date:  2010-03-15       Impact factor: 5.364

8.  Usefulness of Doppler myocardial imaging for identification of mutation carriers of familial hypertrophic cardiomyopathy.

Authors:  Nuno Cardim; Andreas Perrot; Teresa Ferreira; Amadeu Pereira; Karl Joseph Osterziel; Roberto Palma Reis; João Francisco Martins Correia
Journal:  Am J Cardiol       Date:  2002-07-15       Impact factor: 2.778

9.  Genetic and phenotypic characterization of mutations in myosin-binding protein C (MYBPC3) in 81 families with familial hypertrophic cardiomyopathy: total or partial haploinsufficiency.

Authors:  Paal S Andersen; Ole Havndrup; Henning Bundgaard; Lars A Larsen; Jens Vuust; Anders K Pedersen; Keld Kjeldsen; Michael Christiansen
Journal:  Eur J Hum Genet       Date:  2004-08       Impact factor: 4.246

10.  Uptake of genetic counselling and predictive DNA testing in hypertrophic cardiomyopathy.

Authors:  Imke Christiaans; Erwin Birnie; Gouke J Bonsel; Arthur Am Wilde; Irene M van Langen
Journal:  Eur J Hum Genet       Date:  2008-05-14       Impact factor: 4.246

View more
  2 in total

Review 1.  Hypertrophic cardiomyopathy: an updated review on diagnosis, prognosis, and treatment.

Authors:  George Makavos; Chris Κairis; Maria-Eirini Tselegkidi; Theodoros Karamitsos; Angelos G Rigopoulos; Michel Noutsias; Ignatios Ikonomidis
Journal:  Heart Fail Rev       Date:  2019-07       Impact factor: 4.214

2.  The Burden of Early Phenotypes and the Influence of Wall Thickness in Hypertrophic Cardiomyopathy Mutation Carriers: Findings From the HCMNet Study.

Authors:  Carolyn Y Ho; Sharlene M Day; Steven D Colan; Mark W Russell; Jeffrey A Towbin; Mark V Sherrid; Charles E Canter; John L Jefferies; Anne M Murphy; Allison L Cirino; Theodore P Abraham; Matthew Taylor; Luisa Mestroni; David A Bluemke; Petr Jarolim; Ling Shi; Lynn A Sleeper; Christine E Seidman; E John Orav
Journal:  JAMA Cardiol       Date:  2017-04-01       Impact factor: 14.676

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.